Conflict of interest: Nothing to declare.
Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain†
Article first published online: 3 OCT 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 3, pages 433–437, March 2013
How to Cite
Ruggiero, A., Coccia, P., Arena, R., Maurizi, P., Battista, A., Ridola, V., Attinà, G. and Riccardi, R. (2013), Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Pediatr. Blood Cancer, 60: 433–437. doi: 10.1002/pbc.24332
- Issue published online: 15 JAN 2013
- Article first published online: 3 OCT 2012
- Manuscript Accepted: 27 AUG 2012
- Manuscript Received: 11 APR 2012
- cancer pain;
- transdermal patch
The current study investigated the efficacy, safety, tolerability, and compliance of a transdermal buprenorphine delivery system for the management of chronic cancer pain in the pediatric population.
Sixteen pediatric patients with moderate to severe cancer-related pain not satisfactorily controlled with previous non-opioid therapies were enrolled. Transdermal buprenorphine was administered following a 72 hour schedule and rescue medication (tramadol) was allowed for breakthrough pain. Pain intensity was assessed using the Wong–Baker faces pain rating scale (WBS) and other parameters related to the global quality of life were evaluated. Children's evaluations of efficacy, compliance, and tolerability were recorded using numerical scales. Adverse events were monitored during the study and the medications needed to control opioid-related nausea and constipation were recorded.
Eleven patients (68.75%) responded to transdermal buprenorphine after 2 weeks of treatment. Pain intensity measured with WBS decreased from 6.25 at baseline to 1.38 at Day +60 (P < 0.001). All outcome measures of global quality of life (quality of sleep, alimentation, play and activity, speech, and crying) significantly improved over the 60-day study period. Children's evaluations of compliance and tolerability of the drug were always positive over the entire period of treatment. No severe adverse events were recorded. Opioid-related nausea was well controlled with medication on request, and the need for laxative therapy was greater at the end of the second month of treatment.
Transdermal buprenorphine was found to represent an efficient, safe and well tolerated approach to the management of children's chronic cancer pain. Pediatr Blood Cancer 2013; 60: 433–437. © 2012 Wiley Periodicals, Inc.